Zafar Malik

6.9k total citations
57 papers, 592 citations indexed

About

Zafar Malik is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Zafar Malik has authored 57 papers receiving a total of 592 indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Pulmonary and Respiratory Medicine, 20 papers in Oncology and 17 papers in Surgery. Recurrent topics in Zafar Malik's work include Prostate Cancer Treatment and Research (30 papers), Cancer Treatment and Pharmacology (14 papers) and Radiopharmaceutical Chemistry and Applications (12 papers). Zafar Malik is often cited by papers focused on Prostate Cancer Treatment and Research (30 papers), Cancer Treatment and Pharmacology (14 papers) and Radiopharmaceutical Chemistry and Applications (12 papers). Zafar Malik collaborates with scholars based in United Kingdom, Pakistan and France. Zafar Malik's co-authors include Muhammad Zohaib Iqbal, John D. Fenwick, Alan E. Nahum, Chinnamani Eswar, Aamer Nadeem, S H Waqar, Amit Bahl, Alison Birtle, Simon Chowdhury and Johann S. de Bono and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Lancet Oncology.

In The Last Decade

Zafar Malik

56 papers receiving 566 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Zafar Malik United Kingdom	14	330	146	116	104	86	57	592
Bernhard Berger Germany	17	302 0.9×	142 1.0×	232 2.0×	416 4.0×	75 0.9×	52	948
Nirmal Kumar Gupta India	13	119 0.4×	33 0.2×	82 0.7×	194 1.9×	20 0.2×	34	429
Nicola Alessandro Iacovelli Italy	17	272 0.8×	161 1.1×	276 2.4×	267 2.6×	78 0.9×	57	761
Hongkun Wang United States	16	132 0.4×	21 0.1×	186 1.6×	49 0.5×	44 0.5×	61	588
Payal Soni United States	14	516 1.6×	188 1.3×	283 2.4×	179 1.7×	203 2.4×	51	1.1k
Marcus Hudec Austria	14	165 0.5×	21 0.1×	413 3.6×	205 2.0×	4 0.0×	48	854
Stefan Welte Germany	13	90 0.3×	43 0.3×	174 1.5×	228 2.2×	76 0.9×	27	548
Masood A. Khan United Kingdom	18	720 2.2×	106 0.7×	147 1.3×	146 1.4×	24 0.3×	44	1.0k
Ali Khatami Sweden	14	1.3k 3.9×	122 0.8×	364 3.1×	416 4.0×	9 0.1×	31	1.5k
Ray Lin United States	11	272 0.8×	24 0.2×	280 2.4×	59 0.6×	38 0.4×	27	613

Countries citing papers authored by Zafar Malik

Since Specialization

Citations

This map shows the geographic impact of Zafar Malik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zafar Malik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zafar Malik more than expected).

Fields of papers citing papers by Zafar Malik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zafar Malik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zafar Malik. The network helps show where Zafar Malik may publish in the future.

Co-authorship network of co-authors of Zafar Malik

This figure shows the co-authorship network connecting the top 25 collaborators of Zafar Malik. A scholar is included among the top collaborators of Zafar Malik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zafar Malik. Zafar Malik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Houten, Rachel, Nigel Fleeman, James Mahon, et al.. (2023). Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - Open. 7(3). 345–358. 2 indexed citations

Tree, Alison, Clare Griffin, Isabel Syndikus, et al.. (2022). Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial. International Journal of Radiation Oncology*Biology*Physics. 113(2). 305–315. 5 indexed citations

Attard, Gerhardt, Louise Brown, Nigel Clarke, et al.. (2021). LBA4 Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol. Annals of Oncology. 32. S1298–S1298. 5 indexed citations

Staffurth, John, Joanne Haviland, Anna Wilkins, et al.. (2021). Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016). European Urology Oncology. 4(6). 980–992. 23 indexed citations

James, Nicholas D., Hannah Rush, Noel W. Clarke, et al.. (2020). 611O Abiraterone acetate plus prednisolone for hormone-naïve prostate cancer (PCa): Long-term results from metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476). Annals of Oncology. 31. S509–S509. 14 indexed citations

Malik, Zafar & John D. Fenwick. (2020). Radiotherapy to the Primary Tumour for Patients with Metastatic Prostate Cancer: Practice-Changing Results from STAMPEDE. Clinical Oncology. 32(5). 327–329. 3 indexed citations

Khan, Faiz Ullah, Yu Fang, Zakir Khan, et al.. (2020). Occurrence, associated risk factors, and treatment of surgical site infections in Pakistan. SHILAP Revista de lepidopterología. 18. 3254696886–3254696886. 8 indexed citations

James, Nicholas D., Johann S. de Bono, Melissa Spears, et al.. (2017). Adding abiraterone for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Outcomes in non-metastatic (M0) patients from STAMPEDE (NCT00268476). Annals of Oncology. 28. v620–v620. 7 indexed citations

Beer, Tomasz M., Sébastien J. Hotte, Fred Saad, et al.. (2017). Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial. The Lancet Oncology. 18(11). 1532–1542. 67 indexed citations

10.

Brunt, J N H, et al.. (2015). Volumetric modulated arc therapy in prostate cancer patients with metallic hip prostheses in a UK centre. Reports of Practical Oncology & Radiotherapy. 20(4). 273–277. 18 indexed citations

11.

Reddy, Sangeetha M., Scott Kopetz, Jeffrey S. Morris, et al.. (2015). Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. Investigational New Drugs. 33(4). 977–984. 33 indexed citations

12.

Misra, Vivek, et al.. (2014). Reducing febrile neutropenia rates in early breast cancer. Experience of two UK cancer centres. Supportive Care in Cancer. 22(8). 2033–2037. 5 indexed citations

13.

Ali, Shaukat, Tao Yue, & Zafar Malik. (2012). Comprehensively evaluating conformance error rates of applying aspect state machines. 155–166. 4 indexed citations

14.

Malik, Zafar, et al.. (2012). Post docetaxel treatment for castration-resistant prostate cancer (CRPC): Does sequencing matter?. Journal of Clinical Oncology. 30(15_suppl). e15135–e15135. 3 indexed citations

15.

Bavbek, Sevil, Zafar Malik, Giuseppe Di Lorenzo, et al.. (2012). A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results.. Journal of Clinical Oncology. 30(15_suppl). e15112–e15112. 3 indexed citations

16.

Fenwick, John D., Juan Pardo‐Montero, Alan E. Nahum, & Zafar Malik. (2011). Impact of Schedule Duration on Head and Neck Radiotherapy: Accelerated Tumor Repopulation Versus Compensatory Mucosal Proliferation. International Journal of Radiation Oncology*Biology*Physics. 82(2). 1021–1030. 13 indexed citations

17.

Panettieri, Vanessa, Zafar Malik, Chinnamani Eswar, et al.. (2010). Influence of dose calculation algorithms on isotoxic dose-escalation of non-small cell lung cancer radiotherapy. Radiotherapy and Oncology. 97(3). 418–424. 4 indexed citations

18.

Fenwick, John D., Ian Jenkinson, J N H Brunt, et al.. (2010). MRI image-based FE modelling of the pelvis system and bladder filling. Computer Methods in Biomechanics & Biomedical Engineering. 13(6). 669–676. 16 indexed citations

19.

Fenwick, John D., Alan E. Nahum, Zafar Malik, et al.. (2009). Escalation and Intensification of Radiotherapy for Stage III Non-small Cell Lung Cancer: Opportunities for Treatment Improvement. Clinical Oncology. 21(4). 343–360. 43 indexed citations

20.

Fenwick, John D., et al.. (2008). Early Mucosal Reactions During and After Head-and-Neck Radiotherapy: Dependence of Treatment Tolerance on Radiation Dose and Schedule Duration. International Journal of Radiation Oncology*Biology*Physics. 71(2). 625–634. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact